Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?

BACKGROUND. The US Food and Drug Administration authorized Convalescent Plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to use in about 500,000 patients during the first year of the pandemic for the US....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:medRxiv
Main Authors: Casadevall, Arturo, Dragotakes, Quigly, Johnson, Patrick W., Senefeld, Jonathon W., Klassen, Steven A., Wright, R. Scott, Joyner, Michael J, Paneth, Nigel, Carter, Rickey E.
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8043483/
https://ncbi.nlm.nih.gov/pubmed/33851186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.04.07.21255089
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados